



# Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Review article

## Trypanocidal treatment of Chagas disease

Jose A. Pérez-Molina<sup>a,\*</sup>, Clara Crespillo-Andújar<sup>a</sup>, Pau Bosch-Nicolau<sup>b</sup>, Israel Molina<sup>b,c</sup>

<sup>a</sup> National Referral Centre for Tropical Diseases, Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain

<sup>b</sup> Tropical Medicine Unit, Department of Infectious Diseases, Vall d'Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain

<sup>c</sup> Instituto René Rachou-FIOCRUZ Minas, Chagas Disease Research Group, Belo Horizonte, MG, Brazil

### ARTICLE INFO

#### Article history:

Received 19 February 2020

Accepted 18 April 2020

Available online 9 June 2020

#### Keywords:

Benznidazole

Nifurtimox

*Trypanosoma cruzi*

Chagas disease

Neglected diseases

Antiparasitic agents

Pharmacokinetics

Toxicity

### ABSTRACT

Chagas disease is a neglected parasitosis caused by the protozoan parasite *Trypanosoma cruzi*. This infection is present in most Latin American countries, although, due to migratory movements, it is a growing cause for concern in non-endemic countries. The only two drugs currently available for its treatment—benznidazole and nifurtimox—were marketed 50 years ago. While they are very effective for acute and recent infection, and for the prevention of maternofetal transmission, their efficacy declines in people who have chronic infection, especially those older than 18 years of age. In the presence of visceral involvement, parasiticidal treatment is of little or no value. The safety profile of both drugs is far from ideal, with frequent adverse events and high rates of drug discontinuation, mainly in adults. So far, new drugs and new strategies have not been shown to improve the results of the current nitroimidazoles, although the results are promising. In this review, we focus on the aspects that allow clinicians to make the best use of currently available drugs. In addition, we discuss new therapeutic options and ongoing research in the field.

© 2020 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

## Tratamiento tripanocida de la enfermedad de Chagas

### RESUMEN

La enfermedad de Chagas es una parasitosis desatendida causada por el parásito protozoico *Trypanosoma cruzi*. Esta infección está presente en la mayoría de los países de América Latina aunque, debido a los movimientos migratorios, es un motivo de creciente preocupación en los países no endémicos. Los 2 únicos fármacos disponibles en la actualidad para su tratamiento (benznidazol y nifurtimox) se comercializaron hace 50 años. Aunque son muy eficaces para las infecciones agudas y recientes, así como para la prevención de la transmisión maternofetal, su eficacia disminuye en las personas que padecen infecciones crónicas, especialmente en mayores de 18 años. En presencia de afectación visceral, el tratamiento parasiticida tiene poco o ningún valor. El perfil de seguridad de ambos fármacos dista mucho de ser ideal, con efectos adversos frecuentes y altas tasas de abandono del tratamiento, especialmente en adultos. Hasta ahora no se ha demostrado que los nuevos medicamentos y las nuevas estrategias mejoren los resultados de los nitroimidazoles actuales, aunque los resultados son prometedores. En esta revisión nos centramos en los aspectos que permiten a los médicos hacer el mejor uso de los medicamentos disponibles en la actualidad. Además, analizamos las nuevas opciones terapéuticas y las investigaciones en curso en este campo.

© 2020 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Todos los derechos reservados.

#### Palabras clave:

Benznidazol

Nifurtimox

*Trypanosoma cruzi*

Enfermedad de Chagas

Enfermedades desatendidas

Antiparasitarios

Farmacocinética

Toxicidad

\* Corresponding author.

E-mail address: jperez@salud.madrid.org (J.A. Pérez-Molina).

## Introduction

*Trypanosoma cruzi* was recognized by Carlos Chagas in 1909 as the etiological agent of Chagas disease.<sup>1</sup> This parasitosis, is endemic in 21 countries in Latin America and is present from the south of the United States to the north of Argentina and Chile, where it causes 12,000 deaths per year. Estimations from the year 2010 show that nearly 6 million people are infected.<sup>2</sup> Most of them (62.4%) live in the Southern Cone, which has an at-risk population of 70.2 million people, and 38,593 new cases per year (8668 congenital cases). Historically, Chagas disease was confined to rural areas in Latin America. However, as a result of globalisation and an increase in international migrations during the preceding decades, it has become a cause of concern in non-endemic countries. Estimates indicate that up to 347,000 persons are infected in the United States<sup>3</sup> and that up to 123,078 are infected in European countries.<sup>4</sup>

In endemic areas, people contract the disease through contact with the urine or faeces of a *T. cruzi*-infected blood-sucking triatomine insect (also known as the “kissing bug”), through mucous membranes or non-intact skin.<sup>5</sup> Oral transmission is another potential route that is increasing in prevalence in areas like the Amazon basin.<sup>6</sup> Other routes of infection, which are of significant importance in non-endemic areas, are congenital transmission (during pregnancy or childbirth),<sup>7</sup> transmission through blood and blood products<sup>8</sup> or organ transplantation,<sup>9</sup> and transmission through laboratory accidents.<sup>10</sup>

Chagas disease presents two clinical phases: acute and chronic. Acute infections are typically asymptomatic and can occur at any age. Clinical manifestations include fever, lymphadenopathy, hepatosplenomegaly, and inflammation at the inoculum site. Severe forms are rare and account for 1–5% of patients.<sup>5</sup> This phase lasts 4–8 weeks before resolving spontaneously and leaving most patients chronically infected if untreated. Nearly 30–40% of chronically infected patients can develop visceral involvement in a 10–30-year timespan after infection.<sup>11</sup> Most common visceral involvement comprises cardiomyopathy (affecting the conduction system and myocardium) or megaviscera (megaesophagus and/or megacolon). In 10% of cases, mild polyneuropathy can be present.<sup>5</sup> Patients with chronic infection, whether symptomatic or not, constitute the vast majority of people with *T. cruzi* infection.

Acute infections, congenital disease, and reactivations in immunosuppressed patients can be diagnosed through direct visualization or molecular biology methods (mainly, PCR techniques). PCR can also be used for monitoring therapeutic failure.<sup>5,12</sup> During the chronic phase, parasitemia levels are low and intermittent, so diagnosis is based on 2 positive IgG antibodies tests against different *T. cruzi* antigens.<sup>13</sup>

Treatment of *T. cruzi* infection still relies on drugs licensed over 50 years ago: nifurtimox (launched by Bayer in 1965) and benznidazole (launched by Roche in 1971).<sup>14</sup> Their safety and efficacy profiles are far from ideal and are influenced principally by the infection's phase and the age of the patients. In this review, we focus on the factors that allow clinicians to make the best use of currently available drugs. In addition, we discuss new therapeutic options and ongoing research in the field.

## Current drugs used for the treatment of *t. Cruzi* infection

Only two drugs with proven efficacy against *T. cruzi* are available today: benznidazole and nifurtimox.

### Benznidazole

Benznidazole (2-nitro-N-[phenylmethyl]-1H-imidazole-1-acetamide) is a nitroimidazole derivative that was first described as active against *T. cruzi* in the late 1960s.<sup>15</sup> It was introduced for

human treatment in 1971 and showed an efficacy similar to that of nitrofurazone, though with fewer toxic effects.<sup>16</sup> Afterward, different clinical and experimental studies were published using benznidazole as a treatment for acute and chronic Chagas disease; it became the first-line treatment in both situations.<sup>17,18</sup>

As a prodrug, benznidazole is activated by trypanosomal I nitroreductase, releasing other molecules such as dialdehyde glyoxal, which bonds to guanosine bases in DNA and RNA, resulting in its blockade and making the parasite susceptible to oxidative damage in all stages of the *T. cruzi* life cycle.<sup>19,20</sup> In fact, benznidazole acts in a complex manner, resulting in protein, RNA, or DNA synthesis as well as promoting parasitic clearance in infected hosts.<sup>21</sup>

Benznidazole is mainly absorbed from the gastrointestinal tract. Elimination is predominantly renal, though approximately 20% is excreted in the faeces. It has a good oral bioavailability of over 90% following a one-compartment model. After a single oral dose of 100 mg, pharmacokinetics parameters resulted in an area under the curve (AUC) of 46.4 µg h/ml, peak plasma concentrations of 3.5 h, maximal concentrations of 2.2 µg/ml, and a terminal half-life of 12.1 h.<sup>22</sup> Although its pharmacokinetic profile has not been traditionally considered, its understanding can contribute to a proper design of new protocols and reduce bioaccumulation and the risk of toxicity.

### Nifurtimox

Nifurtimox (3-methyl-N-[(5-nitro-2 furanyl)-methylene]-4-morpholinamine 1,1 dioxide) is a nitrofur derivative that was first clinically used in 1969.<sup>23,24</sup> Later studies showed different results based on disease phase, treatment duration, patient age, and geographical area.

Nifurtimox generates nitroanion radicals by nitroreductases that, in the presence of oxygen, produce free radicals that damage *T. cruzi*.<sup>25</sup> Along with benznidazole, this radicals also blocks DNA synthesis and accelerates its degradation. It is effective in eradicating the amastigote, epimastigote, and reproductive forms.

Nifurtimox is absorbed from the gastrointestinal tract and undergoes extensive first-pass hepatic metabolism involving cytochrome P-450 and p-450 reductase. It has little renal excretion (less than 1%). A single oral dose of 15 mg/kg resulted in an AUC of 5.43 ng ml/h and a peak plasma concentration at 2 h with a maximal concentration of 751 ng/ml and a terminal half-life of 2.95 h.<sup>26</sup> Due to its worse toxicity profile, nifurtimox was discontinued and its commercialization suspended in Brazil, Argentina, Chile, and Uruguay from the early 1980s. However, due to a lack of alternatives, it has retained its indication as a second-line treatment when BNZ fails or toxicity occurs.<sup>14</sup> The main pharmacological characteristics of benznidazole and nifurtimox are summarized in Table 1.



## Indications for the treatment of *T. cruzi* infection

### Trypanocidal treatment of acute and congenital Chagas disease

Treatment during the acute phase of Chagas disease is always recommended, regardless of the mechanism of infection, as well as in reactivations in immunosuppressed patients.<sup>27–29</sup> In acute infection, treatment produces symptomatic improvement and the clearance of parasitemia as well as serological negativity in most cases. In immunosuppressed patients, early parasiticidal treatment during reactivations can prevent the development of severe disease.<sup>30</sup>

Although there are no randomized clinical trials that compare benznidazole and nifurtimox, benznidazole is generally preferred due to its better tolerability and tissue penetration, as well as its possibly higher efficacy.<sup>5,28</sup> Benznidazole engages in significant activity during the acute and early phases of *T. cruzi* infection: Serological cure is achieved in up to 100% of patients with

**Table 1**  
Main characteristics of benznidazole and nifurtimox.

Name	Benznidazole	Nifurtimox
Chemical structure		
Dose	Adults: 5–7 mg/kg/24 h Children: 7–10 mg/kg/24 h	Acute: 15 mg/kg/24 h Chronic: 8–10 mg/kg/24 h
Absorption	Gastrointestinal tract	Gastrointestinal tract
Elimination	Renal	First-pass hepatic metabolism
AUC	20% faeces	<10% renal
Peak	46.4 µg/ml/h	5.43 ng/ml/h
Cmax	3.5 h	2 h
Terminal half-life	2.2 µg/ml	751 ng/ml
	12.1 h	2.95 h

congenital disease<sup>31,32</sup> treated during the first year of life and in 76% of patients with acute disease.<sup>33,34</sup> Newborns of mothers with Chagas disease should be tested for *T. cruzi* infection as soon as possible<sup>28,35</sup> because trypanocidal treatment in this setting is highly effective and well-tolerated. A delay in treatment initiation can result in poorer efficacy.<sup>31</sup>

The diagnosis of acute and congenital infection can be carried out by the direct microscopic visualization of trypomastigotes in the blood,<sup>27</sup> though concentration methods such as microhematocrit, and the Strout method.<sup>36</sup> PCR techniques have proven to be very useful in the diagnosis of mother-to-child transmission during the first trimester of life, when such techniques are more sensitive than concentration techniques.<sup>37,38</sup> Also, in neonatal infection, diagnosis can be confirmed based on positive serology results beyond the eighth month of life.<sup>28</sup>

In children, treatment is administered at higher doses than in adults (Table 2).<sup>29</sup> Benznidazole is available in dispersal tablets of 12.5 mg, while nifurtimox in dispersal tablets of 30 mg will be available for paediatric use.<sup>39</sup>

Benznidazole is not commercialized in Spain, so it can be obtained through two methods depending on the autonomous region and hospital policy. It can be acquired through the foreign drug supply section of the Department of Health of each autonomous region upon the presentation of the Spanish health insurance card, an official medical prescription, and a medical report specifying the patient and physician data, the diagnosis that motivates the prescription, and the drug, dosage, and duration of the treatment.<sup>40</sup> The drug can also be acquired at the hospital pharmacy if the hospital had previously requested it from the Department of Health of each autonomous region. In the United States, benznidazole was recently approved by the FDA for patients between 2 and 12 years of age.<sup>41</sup>

Due to an agreement with Bayer, nifurtimox is available free of charge upon a request to the WHO.<sup>42</sup> In Spain, this drug can be obtained free of charge upon request from the WHO through a patient-named programme. It is not currently approved by the FDA, so in the United States, it could be used under the CDC's investigational protocols.<sup>43</sup>

#### Trypanocidal treatment of chronic Chagas disease

The vast majority of patients who do not receive treatment during the acute phase will progress to chronic infection. Most of them will never develop visceral involvement, resulting in a chronic indeterminate phase characterized by a good prognosis, the absence of clinical signs and symptoms, and normal radiological and electrocardiography studies.<sup>44</sup>

The efficacy of treatment seems to decrease as time passes since the incidence of primary infection and is very poor when visceral involvement is established.<sup>45,46</sup> Parasitocidal treatment is generally offered to patients with chronic Chagas disease in the indeterminate phase, especially patients under 18 years of age and patients with mild to moderate disease (Table 2). These patients would likely benefit from treatment and should be informed about the risk-benefit balance of treatment with parasitocidal drugs.<sup>29</sup>

Nifurtimox's disclosed cure rates in the chronic indeterminate phase range from 86% in children below 14 years to 7–8% in adults.<sup>14,47</sup> As for benznidazole, cure rates range from 60 to 94% in children aged up to 13 years<sup>48,49</sup> to 2–40% in adults with late chronic disease, although these values improve with longer follow-up.<sup>33,50–52</sup> Some reports have shown that only 30 days of treatment with benznidazole can be useful for chronically infected adults.<sup>31,50</sup>

Treatment is generally not indicated in patients with moderate to severe cardiomyopathy, as it has not been shown to reduce clinical cardiac events and death as compared to placebo.<sup>45</sup> For patients older than 50 years of age who do not have severe cardiomyopathy, treatment should be individualized.<sup>5,28,29</sup> The treatment of women of childbearing age with chronic Chagas disease has the additional benefit of preventing mother-to-child transmission of *T. cruzi*.<sup>53–56</sup> Therefore, the screening of women who are currently living, or who have lived, in endemic areas, as well as women born to mothers from endemic regions, is key to the prevention of vertical transmission.<sup>35,57</sup>

Pregnancy must be ruled out before the initiation of trypanocidal treatment. The use of benznidazole and nifurtimox is not recommended during pregnancy, mainly because of the scarcity of safety data.<sup>28,29</sup> Nifurtimox has been related to delayed intra-uterine development and lower body weight in rats and mice foetuses born to mothers treated with high doses of up to 125 mg/kg.<sup>58</sup> Benznidazole crosses the placental barrier of pregnant rats and reaches the foetus, binding reactive metabolites to foetal proteins.<sup>59</sup> Both drugs have been associated with chromosomal aberrations in infected children after treatment.<sup>60,61</sup> The accidental intake of trypanocidal drugs during pregnancy is not a criterion for its termination.<sup>28</sup> Parasitocidal treatment is generally recommended in cases of acute infection or reactivation during pregnancy.<sup>62</sup>

Close monitoring of both mother and foetal conditions is necessary in cases of the diagnosis of any phase of Chagas disease during pregnancy. Vertical transmission can occur at any time but is more common during the third trimester of pregnancy.<sup>28,63</sup> The congenital transmission rate for mothers with positive PCR is around 8–18.8% compared to anecdotal cases of transmission in PCR-negative mothers.<sup>12,54,56,64</sup> The infection itself does not justify a Caesarean section.<sup>5,28</sup>

**Table 2**  
Treatment recommendations for acute and chronic Chagas disease.

	Benznidazole	Nifurtimox	Grades of recommendation and levels of evidence <sup>b</sup>
<i>Acute infection</i>			
Congenital cases	10 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	10–15 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	AIII
Vectorial and oral	Children ( $\leq 40$ kg): 7.5–10 mg/kg per day in 2 to 3 daily doses <sup>a</sup> Adults ( $> 40$ kg): 5–7 mg/kg per day in 2 to 3 daily doses <sup>a</sup> Meningoencephalitis: up to 15 mg/kg per day	Children ( $\leq 40$ kg): 10–15 mg/kg per day in 2 to 3 daily doses <sup>a</sup> Adults ( $> 40$ kg): 8–10 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	AIII
Laboratory accidents	5–7 mg/kg per day in 2 to 3 daily doses for 10–14 days	8–10 mg/kg per day in 2 to 3 daily doses for 10–14 days	AIII
Post-transfusion or transplant from an infected donor	5–7 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	8–10 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	AIII
<i>Chronic infection</i>			
Immunocompetent patient	Children ( $\leq 40$ kg): 7.5 mg/kg per day in 2 to 3 daily doses <sup>a</sup> Adults ( $> 40$ kg): 5 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	Children ( $\leq 40$ kg): 10 mg/kg per day in 2 to 3 daily doses <sup>a</sup> Adults ( $> 40$ kg): 8 mg/kg per day in 2 to 3 daily doses <sup>a</sup>	AI for children BIII for adults without severe visceral involvement
HIV-infected patient	Antiparasitic treatment at standard doses. Consider treatment especially when CD4 count $< 200$ cells per $\mu\text{L}$ Start treatment in patients with stable antiretroviral treatment		BIII
Transplant recipients	Benznidazole 5 mg/kg per day is preferred to nifurtimox 8–10 mg/kg per day <sup>a</sup>		BIII
<i>Reactivation</i>			
HIV-infected	Benznidazole 5–7.5 mg/kg per day <sup>a</sup> or nifurtimox 8–10 mg/kg per day. <sup>a</sup> Start antiparasitic treatment as soon as possible. Early initiation of cART (no reports of <i>T. cruzi</i> IRIS) <sup>a</sup> Secondary prophylaxis with benznidazole 5 mg/kg per day 3 times per week or 200 mg daily until CD4 count $> 200$ –250 cells per $\mu\text{L}$ for 6 months and undetectable HIV viral load		AIII
Transplant recipients	Benznidazole 5–7.5 mg/kg per day for 60 days or nifurtimox 8–10 mg/kg per day for 90 days, although longer courses have been recommended Close monitoring for toxicity		AIII

<sup>a</sup> For 60 days.<sup>b</sup> Adapted from the Infectious Disease Society of America United States Public Health Service Grading System.

Treatment during breastfeeding is generally discouraged because, most of the time, there is no urgent need for therapy. It can be considered when this period represents the sole opportunity for the woman's treatment, as happens in some rural Latin American areas.<sup>65</sup> Recent studies have demonstrated a limited and low transference of both trypanocidal drugs through breast milk. Median benznidazole and nifurtimox milk concentrations were 3.8 mg/L (range 0.3–5.9) and 2.15 mg/L (interquartile range 1.32–4.55), respectively.<sup>65,66</sup> Both concentrations are below the 10% cut-off used to guide the risk evaluation of drugs during lactation. Treatment for chronically infected women should be considered after delivery and the breastfeeding period.<sup>28,35</sup>

#### Trypanocidal treatment in immunosuppressed patients

Chagas disease in this population may represent an acute infection in a patient with pre-existing immunosuppression or a reactivation in a patient chronically infected with *T. cruzi*.<sup>30</sup>

Apart from vectorial transmission, an acute *T. cruzi* infection can be acquired through organ or bone marrow transplantation or through blood product infusion. Treatment with benznidazole (see the acute infection treatment in Table 2) is mandatory to control the acute symptoms and improve the prognosis.<sup>30,67</sup>

Chronically infected patients with Chagas disease can present a reactivation in the case of immunosuppression, characterized by an increase in parasitaemia even in the absence of symptoms. The incubation period can be prolonged and symptoms—such as prolonged fever, panniculitis, myocarditis, or meningoencephalitis—can be atypical and serious.<sup>30,67</sup> The risk of reactivation can vary depending on the immunosuppression and

the organ transplanted, from 1.8% in liver transplantation to 23.3%, 27.3%, and 31%, in bone marrow, kidney, and heart transplantation, respectively.<sup>29</sup> Administration of antitrypanosomal prophylaxis to infected recipients is generally not recommended, though it could be considered a pretransplant treatment in potential heart transplant recipients or in living donors infected with *T. cruzi*.<sup>5</sup> Close monitoring (preferably with the Strout method and quantitative PCR) is recommended in order to obtain an early diagnosis of reactivation episodes.<sup>28,30,68</sup> There are no data supporting the reduction of the risk of reactivation with the administration of benznidazole prophylaxis prior to or immediately after transplantation.<sup>68,69</sup> Nevertheless, transplant recipients may benefit from trypanocidal treatment before transplantation in the presence of patent parasitemia.<sup>68</sup>

As for patients coinfecting with *T. cruzi* and HIV, reactivation is closely related to late HIV diagnosis, severe immunosuppression (CD4 cell counts  $< 200$  mm<sup>3</sup>), and a lack of antiretroviral treatment. In these circumstances, the rate of reactivation has been estimated as 39.6%.<sup>5,29,30</sup> Treatment of reactivations should begin with the prompt initiation of antiretroviral therapy as soon as possible after diagnosis. Secondary prophylaxis (see Table 2) is generally needed until the patient reaches CD4 cell counts higher than 200–350 mm<sup>3</sup> and an undetectable HIV-ARN viral load for longer than 6 months.<sup>70</sup> Chronically infected patients may benefit from trypanocidal treatment as non-HIV-infected patients.

In the case of cancer and *T. cruzi* infection, reactivations have been described in patients with compromised cellular immunity (mainly haematological malignancies). As a means of preventing reactivations, these patients may benefit from trypanocidal treatment prior to chemotherapy or immunotherapy.<sup>71</sup>

Reactivation in patients with systemic autoimmune diseases is rare. Available information is limited to some case reports of patients with systemic lupus erythematosus treated with immunosuppressive drugs (azathioprine, mycophenolate mofetil, or ciclosporin).<sup>71–73</sup> In these cases, whenever possible, trypanocidal treatment should be administered before immunosuppression, and close monitoring is indicated to detect reactivations.<sup>74</sup>

#### *Evaluation of the therapeutic response to trypanocidal treatment*

The only current criterion for a cure is to revert the outcome of conventional serological tests to negative.<sup>27</sup> Time to cure depends on the phase of the disease and can vary: 1 year in congenital infection, 3–5 years in the acute phase, 5–10 years in early chronic infection, and 10–25 years in chronically infected adults.<sup>28</sup> A number of surrogate biomarkers (some of them related to the parasite itself) for the cure or progression of the disease are under study. Additionally, immunological and biochemical markers are related to the host response to the parasite. Nevertheless, so far, none of them have been validated for clinical use.<sup>75</sup> The main limitations in the validation of new markers are the possibility of reinfection in endemic areas, the long follow-up period needed to establish the current cure criterion, the lack of consensus over an early therapeutic response, and the role of the parasite genotype.<sup>5,76</sup>

After parasitocidal treatment, it is recommended that patients engage in annual follow-ups that evaluate the serological response<sup>5,28,77</sup> or determine whether there has been a clinical progression, to start prompt therapy for the visceral complications.<sup>5</sup> PCR is useful for detecting therapeutic failure when *T. cruzi* become detectable after treatment, although undetectable values do not indicate a cure.<sup>78</sup>

A closer follow-up is recommended for children, as they achieve cure earlier than do adults. In acute, early congenital infection and reactivations, direct parasitological methods and PCR techniques can be used for monitoring response to treatment.<sup>28,78</sup> In coinfecting transplant recipients, a weekly or biweekly follow-up is indicated during the first 6 months to achieve an early detection of reactivation.<sup>68</sup>

Treatment failure is usually seen as a positive PCR result. If the original treatment indication remains unchanged, retreatment with the same or a different drug for 60 or 90 days is suggested. Combination of therapies and longer drug courses may be considered in this situation.

### **Toxicity of trypanocidal treatment**

#### *Toxicity of benznidazole*

Although drug toxicity is the main limitation for the treatment of Chagas disease, the benznidazole safety profile is still not well understood. Most of the available safety information about benznidazole is based on post-marketing studies, given that no pre-marketing safety studies were performed.<sup>79</sup>

Benznidazole's plausible mechanism of action is through highly reactive products formed during its anaerobic nitroreduction. These products form molecular complexes from covalent bonds with DNA, RNA, proteins, and low-molecular-weight thiols. Nitro radical anion derivatives are also generated when benznidazole is processed by cytochrome P450 reductase and mitochondrial dihydroipoamide dehydrogenase.<sup>77</sup> The interaction between these metabolites and the host DNA, proteins, lipids, or other relevant cellular components is believed to be one of the causes of benznidazole toxicity.<sup>80</sup> In addition, moderate and severe cutaneous reactions seem to be caused by delayed (non-IgE-mediated) hypersensitivity reactions associated with the presence of the HLA-B\*3505 allele.<sup>81</sup>

Overall, benznidazole causes adverse reactions in 44.1% (95% CI 37.2–51.2) of patients—more frequently in adults than in children (51.6 vs. 24.5%). As a consequence, 11.4% (95% CI 8.5–14.5) of them must interrupt their treatment—again, more frequently in adults than in children (14.2 vs. 3.8%).<sup>82</sup> In general, toxicity is moderate and reversible, with severe reactions being reported in only 3% of cases.<sup>82</sup> The majority of patients had more than one AR, with a median of 3 AR.<sup>79,83</sup>

AR tend to appear within the first 12–15 days of treatment. The most common are dermatological in nature, that use to be mild to moderate in most cases.<sup>79,83</sup> An infrequent (<1%) exception is DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), characterized by rash and severe general symptoms such as fever, lymphadenopathy, and blood test abnormalities. DRESS syndrome leads to treatment discontinuation and inpatient management for treatment and follow-up.

Gastrointestinal AR are usually the first expression of toxicity. Similar to general symptoms they usually are mild, do not cause treatment interruption and do not require additional treatment.<sup>79,83</sup> Arthritis is a rare and late AR (day 27, IQR:35) more frequently affecting women, who should interrupt benznidazole use.<sup>79</sup>

Blood cell disturbances (most commonly neutropenia and lymphopenia) tend to appear around 14 days after treatment initiation (IQR:14) generally are mild, though, in the case of persistence, the treatment should be discontinued promptly.<sup>79</sup> Severe thrombocytopenia is a very rare event that can be severe and lead to treatment interruption.<sup>84</sup> Serum biochemistry disturbances (mainly the alteration of the liver function test) appear with a median time onset of around 28.5 days (IQR: 35) and are generally mild and transitory; nevertheless, close monitoring is recommended.<sup>79</sup>

Neurological toxicity (paraesthesia and dysgeusia) typically appears late in the treatment course (approximately 40 days after treatment) and often entails treatment discontinuation.<sup>83</sup> Other rare AR such as psychiatric symptoms (sleeping disorders and anxiety or panic attacks), amenorrhoea, erectile dysfunction, and bronchospasm with basal lung infiltrations have been described.<sup>79</sup> The general incidence, description of symptoms, and recommended management for benznidazole AR are summarized in [Table 3](#).

Factors that have been related to benznidazole toxicity are gender and age. Females seem to have a higher incidence of AR but without higher treatment discontinuation rates than males, while older patients (mainly adults as compared to children) also showed a poorer tolerability profile.<sup>82,85</sup> Other characteristics related to an increased risk of toxicity are being of the white or mulatto races and having a better level of education.<sup>85</sup> No relationship has been found between benznidazole toxicity and its serum concentrations, the use of benznidazole from different manufacturers, or the use of daily doses higher than 300 mg compared to less than 300 mg.<sup>83,86,87</sup> Other strategies that have failed in decreased benznidazole toxicity are the use of progressive doses of benznidazole combined with methylprednisolone, the use of progressive doses of benznidazole lasting 5 days, and the decrease of the duration of treatment to 30 days.<sup>50,87,88</sup>

#### *Toxicity of nifurtimox*

Nifurtimox, a nitrofurane, is reduced by liver microsomes to a nitro anion-free-radical-mediated through NADPH-cytochrome Pe-450 reductase. The free radical formation may be the basic cause of nifurtimox toxicity in mammals.<sup>89</sup> It has been related to defects in spermatogenesis in mice, a lower weight increase and less activity in pregnant rats, and the dose-dependent reduction of body weight in rat fetuses.<sup>58</sup> It has also been related to severe central nervous system toxicity in experimental studies involving rats and dogs.<sup>90</sup> Studies of male rats exposed to oral nifurtimox

**Table 3**  
Description of the most common adverse reactions to benznidazole and nifurtimox.

Adverse reaction (%)	Description of symptoms	Management <sup>a</sup>
<i>Benznidazole (frequency of AR in first-line treatment)</i>		
Dermatological (34–50)	Maculopapular rash, urticaria, pruritus	Antihistamine, corticosteroids/treatment interruption if severe or progressive Symptomatic treatment
Gastrointestinal (5–15)	Epigastralgia, nausea, anorexia, abdominal pain	
General symptoms (10–30)	Headache, asthenia, anxiety, malaise, fever	Symptomatic treatment/consider treatment interruption if fever
Musculoskeletal (3–7)	Arthritis	Symptomatic treatment and treatment interruption
Neurologic (9–16)	Paraesthesia, peripheral neuropathy, dysgeusia	Early treatment interruption/symptomatic treatment
Haematological disturbances (6–15)	Neutropenia, lymphopenia, leucopenia	Monitoring/treatment interruption if progression
Serum biochemistry disturbances (2–12)	Hypertransaminasemia	Monitoring/treatment interruption if progression
<i>Nifurtimox (frequency of AR in first-line treatment)</i>		
Adverse reaction (%)	Description of symptoms	Management <sup>a</sup>
Gastrointestinal (31–35)	Anorexia, nausea, abdominal pain	Symptomatic treatment
Neurologic (21–27)	Amnesia, somnolence, paraesthesia, peripheral neuropathy	Early treatment interruption/symptomatic treatment
Psychiatric (50)	Anxiety, insomnia, depression	Treatment interruption
Musculoskeletal (8–49)	Myalgia, arthralgia	Symptomatic treatment/consider treatment interruption
Dermatological (6–22)	Pruritus, rash, urticaria	Antihistamine, corticosteroids/Treatment interruption if severe or progressive
Blood test abnormalities (13)	Neutropenia, lymphopenia, leucopenia, hypertransaminasemia	Monitoring/treatment interruption if progression
General symptoms (50–84)	Weight loss, asthenia, headache	Symptomatic treatment/consider treatment interruption if fever

AR: Adverse reaction; T: toxicity.

<sup>a</sup> Some authors discontinue transiently or decrease the daily drug dose in the case of moderate AR and after the patient's recovery; reintroduce the drug progressively.<sup>83,87</sup>

demonstrated a significantly higher percentage of malignant and benign tumours than in control groups, though so far this effect has not been demonstrated in human beings.<sup>80,91</sup>

As a first-line treatment, nifurtimox presents a high incidence of AR (80.3–100%) and treatment discontinuation (18.4–43.8%).<sup>91–94</sup> Most frequent and earlier AR are gastrointestinal, with a median time onset of 21 days (1–119), that usually are mild and controlled. General symptoms typically appear early after treatment initiation and use to be of mild to moderate intensity. Neurologic and psychiatric symptoms tend to develop later in the course of treatment and frequently imply treatment discontinuation.<sup>91,93</sup> The global frequency, description, and general management of nifurtimox AR are summarized in [Table 3](#).

The safety profile of nifurtimox, when this drug is prescribed after benznidazole intolerance, is similar to that reported in the literature for patients given nifurtimox as a first-line treatment. Nevertheless, while the rates of AR and treatment discontinuation are equivalent for patients treated in Europe, those rates seem to be higher than the rates reported in endemic areas and in the United States.<sup>95</sup> The overall frequencies of AR and TD in this setting were 64.2% and 49.1%, respectively, with the most common AR being cutaneous hypersensitivity (24.1%), digestive disorders (22.2%), fever (12.9%), neurologic disturbances (11.1%), and depression, anxiety, or insomnia (9.2%).<sup>95</sup>

The toxicity of nifurtimox seems to not be related to the mean starting dosage (600.8 mg vs 580.7 mg).<sup>91</sup> As with benznidazole, the combination of nifurtimox and betamethasone does not improve tolerance.<sup>96</sup>

## New approaches to the treatment of *T. cruzi* infection

### Imidazole derivatives experience

Triazole derivatives act as selective inhibitors of *T. cruzi* ergosterol synthesis with potent intrinsic activity against the parasite in vitro and in vivo models and had been considered promising drugs for the treatment of Chagas disease. Several studies using different ergosterol synthesis inhibitors (ESI) for the treatment of Chagas disease have been published, including ketoconazole, itraconazole, or posaconazole in murine models of acute and chronic Chagas disease and in small human series, with good results.<sup>97–99</sup>

Consequently, different clinical trials were developed to evaluate the efficacy and safety of various triazole derivatives. The CHAGASAZOL trial was designed to compare posaconazole at different doses to benznidazole in qPCR-positive patients. Even in patients receiving the maximum dose approved for human use, posaconazole showed higher treatment failure rates of as much as 80.7% compared to a rate of 38.4% obtained with benznidazole.<sup>100</sup> Attempts to optimize available treatments were made in the STOP-CHAGAS trial, in which the authors compared benznidazole and posaconazole in monotherapy and in combination. In this trial, benznidazole in monotherapy showed a parasitological cure of 86.7%—higher than posaconazole in monotherapy (13.3%) and even higher than both treatments in combination (80%).<sup>101</sup> Later, a ravuconazole prodrug was tested at different doses and compared to standard treatment with benznidazole. After a 12-month follow-up, only 29% of patients treated with high-dose ravuconazole had

sustained parasite response, compared to 82% of patients treated with benznidazole.<sup>102</sup>

A trypanostatic effect on quiescent amastigote forms with low replicative rates in the late chronic stage of Chagas disease has been proposed to explain these results.<sup>103</sup> As far as we know, despite the contradictory evidence of ESI in the animal model, all these results suggest that ESI at the current treatment regimens fails to cure patients with Chagas disease.

Among other candidates, fexinidazole—a new nitroimidazole—is the only one that has reached clinical trials in humans. Its anti-trypanocidal activity has been demonstrated in phase II and phase III clinical development for human African trypanosomiasis.<sup>104</sup> Two proofs-of-concept clinical trials have been carried out (ClinicalTrials.gov Identifier: NCT02498782 and NCT03587766) in Bolivia and Spain, respectively, without any published result yet. A brief description of the recent clinical trials performed with trypanocidal treatment for chronic Chagas disease is summarized in Table 4.

#### Other treatment approaches

The strategy of repositioning established therapeutic agents has also been used in Chagas disease. Although various attempts have been carried out in murine models, and potential treatments have been identified, few drugs have been tested in humans. Allopurinol, a hypoxanthine analogue used to treat hyperuricemic conditions, was also described as a trypanocidal drug in the early 1980s.<sup>105</sup> Discordant results in humans have been published. Apt et al.<sup>106</sup> first published a randomized trial comparing itraconazole, allopurinol, or placebo in patients with chronic Chagas disease. Parasitological cure, assessed with xenodiagnosis and lytic antibody activity, was evident in 44% of those treated with allopurinol compared to 53% with itraconazole and 25% with placebo. On the other hand, Rassi et al.<sup>107</sup> performed a randomized double-blind clinical trial comparing 900 mg of allopurinol daily and placebo with 0% negativization of xenodiagnosis. It was also used in a sequential treatment leading to therapeutic immunological changes and the significant reduction of parasitic loads in murine and human models.<sup>108</sup>

Amiodarone, an antiarrhythmic agent, has demonstrated potent and selective anti-*T. cruzi* activity.<sup>109</sup> Two clinical trials are being tested against Chagas disease. The ATTACH trial (ClinicalTrials.gov Identifier: NCT01722942) aims to assess the trypanocidal effect and its clinical benefit among individuals with mild to moderate chronic Chagas cardiomyopathy.

Meanwhile, the CHAGASICS trial (ClinicalTrials.gov Identifier: NCT01722942) has been designed to compare the efficacy of treatment using implantable cardioverter defibrillator implantation versus amiodarone in the prevention of all-cause mortality in high-risk patients with Chagas cardiomyopathy.

#### New experimental regimens for nitroderivative-based therapy

Because the major drawback of nitroderivative-based therapy is its toxicity, which hampers its efficacy rate, different approaches have been designed to improve its tolerance.

Based on population pharmacokinetic studies, a dose reduction has been proposed as a novel approach. This hypothesis has driven the realization of two randomized clinical trials, which are currently being assessed: the BENDITA<sup>110</sup> and MULTIBENZ studies (ClinicalTrials.gov Identifiers: NCT03378661 and NCT03191162, respectively). Both studies aim to determine the efficacy and safety of different benznidazole regimens in adults who are in the chronic phase of Chagas disease. The primary efficacy endpoint is the parasitological response measured by PCR at the end of treatment and maintained for 12 months. In the BENDITA trial, a randomized,

double-blind, phase-II, placebo-controlled trial conducted in Bolivia between 2016 and 2018, 210 patients were randomized into seven groups (30 patients in each group) of benznidazole on shorter regimens and in combination with E1224: benznidazole 300 mg daily, administered for (a) 8 weeks, (b) 4 weeks, or (c) 2 weeks; (d) benznidazole 150 mg daily for 4 weeks; (e) benznidazole 150 mg daily for 4 weeks in combination with E1224 300 mg weekly; (f) benznidazole 300 mg daily for 8 weeks in combination with E1224 300 mg weekly; and (g) corresponding placebos. The intention-to-treat primary efficacy analysis showed that 89.3% had sustained clearance at 6 months on parasitemia on benznidazole 300 mg for 8 weeks and 4 weeks; 82.8% on benznidazole 300 mg for 2 weeks; 83.3% on benznidazole 150 mg for 4 weeks; 85.2% on benznidazole 150 mg for 4 weeks in combination with E1224; and 82.8% on benznidazole 300 mg weekly in combination with E1224, compared to 3.3% for placebo. Safety results suggested high adherence to treatment in all groups. Six patients (20%) discontinued treatment on benznidazole 300 mg for 8 weeks; 1 (3.3%) for 4 weeks; none for 2 weeks; 1 (3.3%) in benznidazole 150 mg for 4 weeks; 3 (10%) in benznidazole 150 mg for 4 weeks in combination with E1224; and 4 (13.3%) in benznidazole 300 mg weekly in combination with E1224. Most adverse events were mild to moderate, with only 6 patients presenting with serious events (SAE). No SAE were reported in benznidazole 300 mg for 2 weeks and 150 mg for 4 weeks.<sup>111</sup>

The MULTIBENZ study is a phase-II randomized, multi-centre, international study conducted in Brazil, Argentina, Colombia, and Spain, assessing benznidazole at lower doses compared to the standard scheme, in patients with chronic Chagas disease. A total of 240 patients was randomized to receive benznidazole 300 mg daily for 60 days, benznidazole 400 mg daily for 15 days, and 150 mg daily for 60 days, with 80 patients in each group and 60 patients per country.

Two observational studies have been published with schemes using a lower overall dose of benznidazole. Viotti et al. analyzed the efficacy measured through the seroconversion of patients who had to interrupt treatment due to adverse events.<sup>112</sup> Eighty-one adult patients with Chagas disease previously treated with benznidazole for a median of 10 days were followed. Twenty percent of these patients (16/81) were considered cured. In the same group, a new scheme of benznidazole was assessed with intermittent doses of benznidazole at 5 mg/kg/day in 2 daily doses every 5 days for a total of 60 days among 20 patients in the disease's chronic phase. The endpoint of the study was treatment failure assessed by PCR and the number of treatment suspensions, as well as a reduction in the severity of adverse effects. The adverse events ratio was similar to that previously reported in the literature (50%) but with a lower discontinuation rate. (Only 1 patient suspended treatment.)<sup>113</sup>

Another approach explored to reduce the adverse event rates and, therefore, the treatment accomplishment, has been to initially administer benznidazole in an increasing dose. Almost 500 patients received a non-randomly standard dose scheme versus an escalating scheme lasting for 5 days up to a maximum of 300 mg/day. The new scheme did not significantly improve drug tolerability or the treatment discontinuation rates during the first 30 days of treatment.<sup>87</sup>

New strategies with nifurtimox have also been explored. The CHICAMOCHA-3 trial (ClinicalTrials.gov Identifier: NCT02369978) is intended to evaluate the efficacy of both nifurtimox and benznidazole using a conventional dose for 60 days or a half-dose for 120 days.

A novel clinical trial has recently started its recruitment phase. The TESEO trial (ClinicalTrials.gov Identifier: NCT03981523) will evaluate the efficacy and tolerability of both benznidazole and nifurtimox by lowering the dose and the treatment duration.

**Table 4**  
Recent clinical trials including etiological treatment for chronic Chagas disease.

Ref	Year <sup>a</sup>	Name	NTC number	Phase	Design	Countries	Patients	Age	Treatment groups	End-point	Follow-up	Results <sup>b</sup>
<sup>100</sup>	2014	CHAGASAZOL	NCT01162967	2	Randomized, open-label	Spain	78	39 ± 9 years	-POS 400 mg bid × 60d -POS 100 mg bid × 60d -BZN 150 mg bid × 60d	Quantitative PCR	10 months	POS (high dose) 19% POS (low dose) 8% BZN 62%
<sup>45</sup>	2015	BENEFIT	NCT00123916	3	Randomized, double-blind, placebo-controlled trial	Argentina, Bolivia, Brazil, Colombia, El Salvador	2854	55.3 ± 10.1 years	-BZN 5 mg/Kg/d × 60d (since 2009 300 mg per day, 40–80 days) -Placebo × 60d	-Death or cardiac event - Qualitative PCR	7 years	BZN: 27.5% composite outcome; 46.7% negative PCR (5y) Placebo: 29.1% composite outcome, 31% negative PCR (5Y)
<sup>101</sup>	2017	STOP-CHAGAS	NCT01377480	2	Randomized, placebo-controlled, POS single-blind but BNZ open-label	Argentina, Chile, Spain, Colombia, Guatemala, Mexico	120	38.6 ± 8.1 years	-POS 400 mg bid -BNZ 200 mg + placebo bid -BNZ 200 mg bid + POS 400 mg -Placebo 10 mg b.i.d.	Qualitative PCR	180 days	POS 400 mg: 13.3% BNZ + placebo: 86.7% BNZ + POS: 80% Placebo: 10%
<sup>102</sup>	2018	PoC Study E1224	NCT01489228	2	Randomized, double-blind, placebo- and active-controlled	Bolivia	231	31.1 ± 8.7 years	-E1224 8000 mg 8 w -E1224 2000 mg 8 w -E1224 2400 mg 4 w + placebo 4 w - BZD 5 mg/Kg/d 60d -Placebo 8 w	Quantitative PCR	12 months	E1224 high dose: 29% E1224 low dose: 0% E1224 short dose: 0% BZN: 82%
<sup>129</sup>	Preliminary results	TRAENA	NCT02386358	3	Randomized, double-blind, placebo-controlled	Argentina	910	20–55 years	-BNZ 5 mg/Kg/d × 60d -Placebo bid	ELISAs, F29, quantitative PCR	11 years	BNZ: 31.7% (ELISAsc), 40% (F29), 90% (qPCR) Placebo: 13.3% (ELISAsc), 13.5% (F29), 42% (qPCR)
<sup>110</sup>	Preliminary results	BENDITA	NCT03378661	2	Randomized, double-blind, placebo-controlled	Bolivia	210	18–50 years	- BZD 300 mg/d 8 w - BZD 300 mg/d 4 w - BZD 300 mg/d 2 w - BZD 150 mg/d 4 w - BZD 150 mg/d + E1224 300 mg/w 4 w - BZD 300 mg/d + E1224 300 mg/w 8 w - Placebo 8w	Quantitative PCR	12 months	BZD 300 mg/d 8 w: 82.8% BZD 300 mg/d 4 w: 89.3% BZD 300 mg/d 2 w: 79.3% BZD 150 mg/d 4 w: 80% BZD 150 mg/d + E1224 300 mg/w 4 w: 85.2% BZD 300 mg/d + E1224 300 mg/w 8 w: 82.8%



**Table 4** (Continued)

Ref	Year <sup>a</sup>	Name	NTC number	Phase	Design	Countries	Patients	Age	Treatment groups	End-point	Follow-up	Results <sup>b</sup>
130	Ongoing	PoC Study FEXINIDAZOLE	NCT02498782	2	Randomized, double-blind, placebo- controlled	Bolivia, Argentina, Spain	140	18–50 years	-FEXI 600 mg + placebo qd × 10d -FEXI 1200 mg qd × 3d followed by placebo qd × 7d -FEXI 600 mg + placebo qd × 3d followed by FEXI 1200 mg qd × 4d followed by Placebo qd × 3d	Quantitative PCR	12 months	Ongoing
131	Ongoing	CHICAMOCHA- 3	NCT02369978	3	Randomized, blinded, parallel trial	Colombia, Argentina	500	18–50 years	-NFX 8 mg/Kg/d × 60d followed by Placebo × 60d -NFX 4 mg/Kg/d × 120d -BZN 5 mg/Kg/d × 60d followed by Placebo 60d -BZN 2.5 mg/Kg/d × 120d -Placebo 120d	Quantitative PCR	12 months	Ongoing
132	Ongoing	MULTIBENZ	NCT03191162	2	Randomized, double-blind, parallel trial	Spain, Colombia, Argentina, Brazil	240	>18 years	-BZN 300 mg/d × 60d -BZN 150 mg/d × 60d -BZN 400 mg/d × 15d	Quantitative PCR	12 months	Ongoing
133	Ongoing	ATTACH	NCT03193749	3	Randomized double-blind, placebo- controlled	Colombia	200 CCC (structural and rhythm abnormali- ties)	18–70 years	-Amiodarone hydrochloride 200 mg qd × 6 months -Placebo qd × 6 months	Qualitative PCR Composite end-point CV events	6 months	Ongoing
134	Ongoing	BETTY	NCT03672487	3	Randomized double-blind, placebo- controlled	Argentina	600	Women of childbearing age >13 years	-BZN 300 mg/d × 60d -BZN 150 mg/d × 30d	Quantitative PCR	10 months	Ongoing

Abbreviations: BNZ: Benznidazole, NFX: Nifurtimox, POS: Posaconazole, E1224: Ravuconazole prodrug, FEXI: Fexinidazole, d: day, PCR: Polymerase-chain-reaction, qPCR: quantitative polymerase-chain-reaction, CCC: chronic Chagas cardiomyopathy.

<sup>a</sup> Year of publication.

<sup>b</sup> Results are expressed as % of negative PCR at the end of follow-up unless otherwise specified.

## Challenges in the treatment of *T. cruzi* infection

### Surrogate markers for a cure

Chagas disease therapeutic response is currently based on a reversion to negative results in conventional serological tests, which may take 10–20 years in chronic infections.<sup>33</sup> Parasitological methods including the PCR have low sensitivity and have not demonstrated a correlation with clinical outcomes after treatment in the chronic phase.<sup>45</sup> Therefore, long-term follow-up is mandatory for patients treated in the chronic phase with its related costs. Another important derived issue is the lack of short-term markers of clinical response with which to evaluate the effectiveness of therapies in clinical trials.

Several studies have recently tried to identify surrogate biomarkers of a cure with different approximations. Vallejo et al. evaluated the adaptative immune response in treated patients compared to control patients showing significantly lower immune activation and lower regulatory T-cell counts, with an increased Th17 and Th1 response.<sup>114</sup> Other studies have also described a change in the regulatory pattern of interferon- $\gamma$  and cytokines.<sup>115</sup> In addition, hypercoagulability has been studied in Chagas disease patients, with Pinazo et al. proposing haemostasis parameters as an early surrogate biomarker for an early cure.<sup>116</sup> An upregulation of metabolic biomarkers such as A-I (APOA1) and specific fragments of human fibronectin (FN1) have also been described. Santamaría et al. published its normalization after 3 years in half of treated patients.<sup>117</sup> One specific antibody response (antibody 3, Ab3) was also evaluated in 1635 chronic patients of the SamiTrop cohort. It showed a strong correlation with *T. cruzi* parasite persistence as determined by a *T. cruzi* PCR-positive result with a significant decline in its signal after trypanocidal treatment.<sup>118</sup> Finally, various *T. cruzi* antigens and their sera reactivity have been evaluated, though the results are still far from ideal.<sup>119</sup> Hence, the research of new reliable biomarkers, although prolific, has produced limited results. Further long-term evaluation must be done to prove the usefulness of biomarkers in clinical practice.

### Development of new trypanocidal drugs

Recent advances both in knowledge about the parasite and in the drug discovery process have led to the identification of new targets and new compounds. Several families have been tested: inhibitors of trypanothione metabolism, inhibitors of cysteine proteases, lysophospholipid analogues, modern ergosterol biosynthesis inhibitors, and bis-triazole derivatives, among others. Unfortunately, the results obtained in the animal model have stopped its posterior clinical development, for either lack of efficacy (a non-sterile cure) or its toxicity.

However, likely, among these new compounds, oxaborole derivatives have shown the most promising results in preclinical studies.<sup>120</sup> Moreover, SCYX-7158, an orally active benzoxaborole, has been tested against human African trypanosomiasis (ClinicalTrials.gov Identifier: NCT03087955). The results have not yet been published. This is reminiscent of the same clinical strategy used with fexinidazole. What makes that new family remarkable is its potential activity among other kinetoplastids such as leishmania.<sup>121</sup>

### Access to treatment

Access to both benznidazole and nifurtimox represents a challenge in most non-endemic countries, as well as for patients living in poor rural areas of endemic countries, due to restricted access to health care systems and limited provider awareness, among other causes.<sup>122–124</sup> Even though benznidazole was recently approved

by the FDA,<sup>41</sup> many barriers to accessing this treatment remain for Chagas disease patients in the United States.<sup>122</sup> Additionally, in Latin America (at least in 14 countries), an important gap exists between the current demand for drugs and the prevalence rate estimations of the disease, proving that much work remains to be done in terms of diagnosing and treating Chagas disease globally.<sup>125</sup>

A shortage of benznidazole occurred in 2011, leaving thousands of patients worldwide without access to this first option for treatment. During that period, in Spain (the European country with the highest prevalence of Chagas disease), a lack of access to benznidazole lasted over a year, forcing a prioritizing of the treatment for acute infection, neonates, and immunosuppressed patients.<sup>126</sup> Nowadays, benznidazole is available in Spain and, depending on the region in which the patient lives, can be obtained through the hospital pharmacy or the regional health service of the Foreign Drugs Supply Department, with a different cost depending on the regional policy.<sup>127</sup> Even though the WHO announced the availability of benznidazole free of charge for patients younger than 18 years,<sup>35</sup> to date, this has not been implemented in Spain.

While investment in Chagas disease has increased throughout the years, and while institutions and non-profit organizations are working to facilitate the diagnosis and access to health care of patients, there is still much room for improvement.<sup>128</sup> More effective, better-tolerated, and low-cost drugs are urgently needed.

## Funding

Funding was provided by ISCIII (Instituto de Salud Carlos III), project RD16/0027/0020. Red de Enfermedades Tropicales, Subprograma RETICS (Redes Temáticas de Investigación Cooperativa en Salud), and FEDER (Fondo Europeo de Desarrollo Regional).

## References

1. Chagas C. Nova tripanozomíaze humana: estudos sobre a morfologia e o ciclo evolutivo do *Schizotrypanum cruzi* n. gen., n. sp., agente etiológico de nova entidade morbida do homem. *Mem Inst Oswaldo Cruz.* 1909;1:159–218.
2. WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. *Wkly Epidemiol Rec.* 2015;90:33–43.
3. Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the burden of Chagas disease in the United States. *PLoS Negl Trop Dis.* 2016;10:e0005033. <https://doi.org/10.1371/journal.pntd.0005033>
4. Requena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DAJ, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. *PLoS Negl Trop Dis.* 2015;9:e0003540. <http://dx.doi.org/10.1371/journal.pntd.0003540>.
5. Perez-Molina JA, Molina I. Chagas disease. *Lancet.* 2018;391:82–94. [http://dx.doi.org/10.1016/S0140-6736\(17\)31612-4](http://dx.doi.org/10.1016/S0140-6736(17)31612-4).
6. Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. *Clin Infect Dis.* 2012;54:845–52. <http://dx.doi.org/10.1093/cid/cir956>.
7. Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P. Frequency of the congenital transmission of *Trypanosoma cruzi*: a systematic review and meta-analysis. *BJOG An Int J Obstet Gynaecol.* 2013;121:22–33. <http://dx.doi.org/10.1111/1471-0528.12396>.
8. El Ghouzi M-H, Boiret E, Wind F, Brochard C, Fittere S, Paris L, et al. Testing blood donors for Chagas disease in the Paris area France: first results after 18 months of screening. *Transfusion.* 2010;50:575–83. <http://dx.doi.org/10.1111/j.1537-2995.2009.02476.x>.
9. Pinazo M-J, Miranda B, Rodríguez-Villar C, Altclas J, Serra MB, García-Otero EC, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. *Transplant Rev.* 2011;25:91–101. <http://dx.doi.org/10.1016/j.trre.2010.12.002>.
10. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. *Clin Microbiol Rev.* 2001;14:659–88. <http://dx.doi.org/10.1128/CMR.14.3.659-688.2001>.
11. Coura JR, de Abreu LL, Pereira JB, Willcox HP. Morbidity in Chagas' disease. IV. Longitudinal study of 10 years in Pains and Iguatama, Minas Gerais, Brazil. *Memorias Inst Oswaldo Cruz.* 1985;80:73–80. <http://dx.doi.org/10.1590/s0074-02761985000100011>.
12. Bern C, Verastegui M, Gilman RH, LaFuente C, Galdos-Cardenas G, Calderon M, et al. Congenital *Trypanosoma cruzi* transmission in Santa Cruz, Bolivia. *Clin Infect Dis.* 2009;49:1667–74. <http://dx.doi.org/10.1086/648070>.
13. Brasil PEEA, De Castro L, Hasslocher-Moreno AM, Sangenis LHC, Braga JU. ELISA versus PCR for diagnosis of chronic Chagas disease:

- systematic review and meta-analysis. *BMC Infect Dis.* 2010;10:337, <https://doi.org/10.1186/1471-2334-10-337>
14. Rodrigues Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. *Memorias Inst Oswaldo Cruz.* 2002;97:3–24, <http://dx.doi.org/10.1590/s0074-02762002000100001>.
  15. Grunberg E, Beskid G, Cleeland R, DeLorenzo WF, Titsworth E, Scholer HJ, et al. Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives. *Antimicrob Agents Chemother.* 1967;7:513–9.
  16. Ferreira HO. Tratamento da infecção chagásica com o RO 7-1051. In: *X Congresso Soc Bras Med Trop (Curitiba) Sumário das Comunicações.* 1974.
  17. Schenone H, Concha L, Aranda R, Rojas A, Alfaro E, Knierin ERM. Atividade quimioterápica de um derivado nitroimidazolacetamida na infecção chagásica crônica. *Bol Chil Parasitol.* 1975;30:91–3.
  18. Ferreira HO. Ensaio terapêutico-clínico com benznidazol na doença de Chagas. *Rev Inst Med Trop Sao Paulo.* 1976;18:357–64.
  19. Patterson S, Wyllie S. Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. *Trends Parasitol.* 2014;30:289–98, <http://dx.doi.org/10.1016/j.pt.2014.04.003>.
  20. Trochine A, Creek DJ, Faral-Tello P, Barrett MP, Robello C. Benznidazole biotransformation and multiple targets in *Trypanosoma cruzi* revealed by metabolomics. *PLoS Negl Trop Dis.* 2014;8:e2844, <http://dx.doi.org/10.1371/journal.pntd.0002844>.
  21. Apt BW, Zulantay AI. Estado actual en el tratamiento de la enfermedad de Chagas. *Rev Med Chil.* 2011;139:247–57, <http://dx.doi.org/10.4067/S0034-98872011000200016>.
  22. Molina I, Salvador F, Sánchez-Montalvá A, Artaza MA, Moreno R, Perin L, et al. Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials. *Antimicrob Agents Chemother.* 2017;61:e01912–1916, <http://dx.doi.org/10.1128/AAC.01912-16>.
  23. Cançado JR, Marra UD, Lopes M, et al. Toxicity and therapeutic value of Bay 2502 in chronic Chagas' disease in 3 dosage schemes. *Bol Chil Parasitol.* 1969;24:28–32.
  24. Bocca Tourres CL. Acute period of Chagas' disease and its treatment with Bay 2502. *Bol Chil Parasitol.* 1969;24:24–7.
  25. Docampo R, Moreno SNJ, Stoppani AOM. Nitrofurantoin enhancement of microsomal electron transport, superoxide anion production and lipid peroxidation. *Arch Biochem Biophys.* 1981;207:316–24, [http://dx.doi.org/10.1016/0003-9861\(81\)90039-4](http://dx.doi.org/10.1016/0003-9861(81)90039-4).
  26. Paulos C, Paredes J, Vasquez I, Thambo S, Arancibia A, Gonzalez-Martin G. Pharmacokinetics of a nitrofurantoin compound, nifurtimox, in healthy volunteers. *Int J Clin Pharmacol Ther Toxicol.* 1989;27:454–7.
  27. WHO Expert Committee. Control of Chagas disease. *World Health Organ Tech Rep Ser.* 2002;905:i-vi, 1–109. Available from: <https://apps.who.int/iris/handle/10665/42443>
  28. Dias JCP, Ramos AN, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et al. 2nd Brazilian Consensus on Chagas disease, 2015. *Rev Soc Bras Med Trop.* 2016;49 Suppl. 1:3–60, <http://dx.doi.org/10.1590/0037-8682-0505-2016>.
  29. Organización Panamericana de la Salud. Guía para el diagnóstico y el tratamiento de la enfermedad de Chagas. Washington, D.C.: OPS; 2018. Available from: [http://iris.paho.org/xmlui/bitstream/handle/123456789/49653/9789275320433\\_spa.pdf?sequence=9&isAllowed=y](http://iris.paho.org/xmlui/bitstream/handle/123456789/49653/9789275320433_spa.pdf?sequence=9&isAllowed=y)
  30. Bern C. Chagas disease in the immunosuppressed host. *Curr Opin Infect Dis.* 2012;450–7, <http://dx.doi.org/10.1097/QCO.0b013e328354f179>.
  31. Schijman AG. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. *J Antimicrob Chemother.* 2003;52:441–9, <http://dx.doi.org/10.1093/jac/dkg338>.
  32. Russomando G, De Tomassone MM, De Guillen I, Acosta N, Vera N, Almiron M, et al. Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. *Am J Trop Med Hyg.* 1998;59:487–91, <http://dx.doi.org/10.1016/bs.apar.2016.10.001>.
  33. Cançado JR. Criteria of Chagas disease cure. *Mem Inst Oswaldo Cruz.* 1999;94 Suppl. 1:331–5, <http://dx.doi.org/10.1590/s0074-40276199900070006>.
  34. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. *Rev Inst Med Trop Sao Paulo.* 2002;44:29–37, <http://dx.doi.org/10.1590/S0036-64665200200010000>.
  35. Carlier Y, Altcheh J, Angheben A, Freilich H, Luquetti AO, Schijman AG, et al. Congenital Chagas disease: updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of child-bearing age, and pregnant women. *PLoS Negl Trop Dis.* 2019;13:e0007694, <http://dx.doi.org/10.1371/journal.pntd.6940007>.
  36. Strout RG. A method for concentrating hemoflagellates. *J Parasitol.* 1962;48:100.
  37. Messenger LA, Bern C. Congenital Chagas disease. *Curr Opin Infect Dis.* 2018;31:415–21, <http://dx.doi.org/10.1097/QCO.0000000000000478>.
  38. Bua J, Volta BJ, Perrone AE, Scollo K, Velázquez EB, Ruiz AM, et al. How to improve the early diagnosis of *Trypanosoma cruzi* infection: relationship between validated conventional diagnosis and quantitative DNA amplification in congenitally infected children. *PLoS Negl Trop Dis.* 2013;17:e2476, <http://dx.doi.org/10.1371/journal.pntd.4760002>.
  39. Carlier Y, Sosa-Estani S, Luquetti AO, Buekens P. Congenital Chagas disease: an update. *Mem Inst Oswaldo Cruz.* 2015;110:363–8, <http://dx.doi.org/10.1590/0074-027610140405>.
  40. BOE.es - Documento BOE-A-2009-12002 [Internet]. Available from: <https://www.boe.es/buscar/doc.php?id=BOE-A-2009-12002> [cited 29.11.19].
  41. FDA approves first U.S. treatment for Chagas disease FDA [Internet]. Available from: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-us-treatment-chagas-disease> [cited 29.11.19].
  42. WHO Treatment of Chagas disease [Internet]. Available from: [https://www.who.int/chagas/disease/home\\_treatment/en/](https://www.who.int/chagas/disease/home_treatment/en/) [cited 28.11.19].
  43. CDC - Chagas Disease - Resources for Health Professionals - Antiparasitic Treatment [Internet]. Available from: [https://www.cdc.gov/parasites/chagas/health\\_professionals/tx.html](https://www.cdc.gov/parasites/chagas/health_professionals/tx.html) [cited 28.11.19].
  44. Dias JCP. The indeterminate form of human chronic Chagas' disease: a clinical epidemiological review. *Rev Soc Bras Med Trop.* 1989;22:147–56, <http://dx.doi.org/10.1590/S0037-78682198900030000>.
  45. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. *N Engl J Med.* 2015;373:1295–306, <http://dx.doi.org/10.1056/NEJMoa1507574>.
  46. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. *Mem Inst Oswaldo Cruz.* 2011;106:641–5, <http://dx.doi.org/10.1590/S0074-02762011000600001>.
  47. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. Estudio longitudinal e quimioterapia específica em crianças, com doença de Chagas crônica, residentes em área de baixa endemicidade da República Argentina. *Rev Soc Bras Med Trop.* 2004;37:365–75, <http://dx.doi.org/10.1590/S0037-18682200400050000>.
  48. Sgambatti de Andrade ALS, Zicker F, de Oliveira RM, Almeida e Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early *Trypanosoma cruzi* infection. *Lancet.* 1996;348:1407–13, [http://dx.doi.org/10.1016/s0140-6736\(96\)8-10412](http://dx.doi.org/10.1016/s0140-6736(96)8-10412).
  49. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BMYC. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. *Am J Trop Med Hyg.* 1998;59:526–9, <http://dx.doi.org/10.4269/ajtmh.1998.59.526>.
  50. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. *Ann Intern Med.* 2006;144:724, <http://dx.doi.org/10.7326/0003-4819-144-10-200605160-00006>.
  51. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. *Rev Soc Bras Med Trop.* 2007;40:1–10, <http://dx.doi.org/10.1590/s0037-18682200700010000>.
  52. Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease Evaluation of specific antiparasitic treatment. *Retrospective-prospective study of antiparasitic therapy.* *Rev Fac Cien Med Univ Nac Cordoba.* 2000;57:135–62.
  53. Fabbro DL, Danesi E, Olivera V, Codebó MO, Denner S, Heredia C, et al. Trypanocide treatment of women infected with *Trypanosoma cruzi* and its effect on preventing congenital Chagas. *PLoS Negl Trop Dis.* 2014;20:e3312, <http://dx.doi.org/10.1371/journal.pntd.0003312>.
  54. Murcia L, Simón M, Carrilero B, Roig M, Segovia M. Treatment of infected women of childbearing age prevents congenital *Trypanosoma cruzi* infection by eliminating the parasitemia detected by PCR. *J Infect Dis.* 2017;215:1452–8, <http://dx.doi.org/10.1093/infdis/jix087>.
  55. Sosa-Estani S, Cura E, Velazquez E, Yampotis C, Segura EL. Etiological treatment of young women infected with *Trypanosoma cruzi*, and prevention of congenital transmission. *Rev Soc Bras Med Trop.* 2009;42:484–7, <http://dx.doi.org/10.1590/s0037-86822009000500002>.
  56. Bua J, Volta BJ, Velazquez EB, Ruiz AM, De Rissio AM, Cardoni RL. Vertical transmission of *Trypanosoma cruzi* infection: quantification of parasite burden in mothers and their children by parasite DNA amplification. *Trans R Soc Trop Med Hyg.* 2012;106:623–8, <http://dx.doi.org/10.1016/j.trstmh.2012.03.015>.
  57. Negrette OS. High prevalence of congenital *Trypanosoma cruzi* infection and family clustering in Salta, Argentina. *Pediatrics.* 2005;115:e668–72, <http://dx.doi.org/10.1542/peds.2004-1732>.
  58. Lorke D. Embryotoxicity studies of nifurtimox in rats and mice and study of fertility and general reproductive performance. *Arzneimittel-Forschung/Drug Res.* 1972;22:1603–7.
  59. De Toranzo EGD, Masana M, Castro JA. Administration of benznidazole, a chemotherapeutic agent against Chagas' disease, to pregnant rats. Covalent binding of reactive metabolites to fetal and maternal proteins. *Arch Int Pharmacodyn Ther.* 1984;272:17–23.
  60. Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Assessment of cytogenetic damage in chagasic children treated with benznidazole. *Mutat Res Toxicol.* 1988;206:217–20, [http://dx.doi.org/10.1016/0165-1218\(88\)90163-2](http://dx.doi.org/10.1016/0165-1218(88)90163-2).
  61. Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. *Mutat Res Toxicol.* 1989;224:263–7, [http://dx.doi.org/10.1016/0165-1218\(89\)90165-1](http://dx.doi.org/10.1016/0165-1218(89)90165-1).
  62. Corrêa VR, Barbosa FG, Melo Junior CA, deCastro LFD, deAndrade Junior HF, de Nascimento N. Uneventful benznidazole treatment of acute Chagas disease during pregnancy: a case report. *Rev Soc Bras Med Trop.* 2014;47:397–400, <http://dx.doi.org/10.1590/0037-8682-0250-2013>.
  63. Brutus L, Castillo H, Bernal C, Salas NA, Schneider D, Santalla JA, et al. Short report: detectable *Trypanosoma cruzi* parasitemia during pregnancy and delivery as a risk factor for congenital chagas disease. *Am J Trop Med Hyg.* 2010;83:1044–7, <http://dx.doi.org/10.4269/ajtmh.2010.10-0326>.

64. Buekens P, Cafferata ML, Alger J, Althabe F, Belizán JM, Bustamante N, et al. Congenital transmission of *Trypanosoma cruzi* in Argentina Honduras, and Mexico: an observational prospective study. *Am J Trop Med Hyg.* 2018;98:478–85, <http://dx.doi.org/10.4269/ajtmh.17-0516>.
65. Moroni S, Marson ME, Moscatelli G, Mastrantonio G, Bisio M, Gonzalez N, et al. Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease. *PLoS Negl Trop Dis.* 2019;13:e0007647, <https://doi.org/10.1371/journal.pntd.0007647>
66. García-Bourneissen F, Moroni S, Marson ME, Moscatelli G, Mastrantonio G, Bisio M, et al. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. *Arch Dis Child.* 2015;100:90–4, <http://dx.doi.org/10.1136/archdischild.2014.028111>
67. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in transplant working group. *Am J Transplant.* 2011;11:672–80, <http://dx.doi.org/10.1111/j.1600-6143.2011.03444.x>.
68. Altclas J, Arselán S, Barcán L, Diez M, Gadano A, Jacob N, et al. Chagas' disease and solid organ transplantation. *Transplant Proc.* 2010;42:3354–9, <http://dx.doi.org/10.1016/j.transproceed.2010.09.019>.
69. Campos SV, Strabelli TMV, Amato Neto V, Silva CP, Bacal F, Bocchi EA, et al. Risk factors for Chagas' disease reactivation after heart transplantation. *J Hear Lung Transplant.* 2008;27:597–602, <http://dx.doi.org/10.1016/j.jacc.2017.08.004>.
70. Pérez-Molina JA, Rodríguez-Guardado A, Soriano A, Pinazo M-J, Carrilero B, García-Rodríguez M, et al. Guidelines on the treatment of chronic coinfection by *Trypanosoma cruzi* and HIV outside endemic areas. *HIV Clin Trials.* 2011;12:287–98, <http://dx.doi.org/10.1310/hct1206-287>.
71. Pérez-Molina JA, Perez AM, Norman FF, Monge-Maillou B, López-Vélez R. Old and new challenges in Chagas disease. *Lancet Infect Dis.* 2015;15:1347–56, [http://dx.doi.org/10.1016/S1473-3099\(15\)00243-1](http://dx.doi.org/10.1016/S1473-3099(15)00243-1).
72. Gascón J, López-Chejade PL, Espinosa G, Urbina JA, Gállego M, Pinazo M-J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. *Am J Trop Med Hyg.* 2010;82:583–7, <http://dx.doi.org/10.4269/ajtmh.2010.09-0620>.
73. Salvador F, Sánchez-Montalvá A, Valerio L, Serre N, Roure S, Treviño B, et al. Immunosuppression and Chagas disease; experience from a non-endemic country. *Clin Microbiol Infect.* 2015;21:854–60, <http://dx.doi.org/10.1016/j.cmi.2015.05.033>.
74. Pinazo M-J, Espinosa G, Cortes-Lletget C, Posada E de J, Aldasoro E, Oliveira I, et al. Immunosuppression and Chagas disease: a management challenge. *PLoS Negl Trop Dis.* 2013;7:e1965, <https://doi.org/10.1371/journal.pntd.0001965>
75. Pinazo M-J, Thomas M-C, Bustamante J, de Almeida IC, Lopez M-C, Gascon J. Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. *Mem Inst Oswaldo Cruz.* 2015;110:422–32, <http://dx.doi.org/10.1590/0074-02760140435>.
76. Pinazo MJ, Thomas MC, Bua J, Perrone A, Schijman AG, Viotti RJ, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. *Expert Rev Anti Infect Ther.* 2014;12:479–96, <http://dx.doi.org/10.1586/14787210.2014.899150>.
77. Caldas IS, Santos EG, Novaes RD. An evaluation of benznidazole as a Chagas disease therapeutic. *Expert Opin Pharmacother.* 2019;20:1797–807, <http://dx.doi.org/10.1080/14656566.2019.1650915>.
78. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas disease in the United States. *JAMA.* 2007;298:2171, <http://dx.doi.org/10.1001/jama.298.18.2171>.
79. Aldasoro E, Posada E, Requena-Méndez A, Calvo-Cano A, Serret N, Casellas A, et al. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. *J Antimicrob Chemother.* 2018;73:1060–7, <http://dx.doi.org/10.1093/jac/dkx516>.
80. Castro JA, DeMecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). *Hum Exp Toxicol.* 2006;25:471–9, <http://dx.doi.org/10.1191/0960327106het6530a>.
81. Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, Sala-Cunill A, Viñas L, García-Prat M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. *Clin Infect Dis.* 2015;61:1688–94, <http://dx.doi.org/10.1093/cid/civ690>.
82. Crespillo-Andújar C, Venanzi-Rullo E, López-Vélez R, Monge-Maillou B, Norman F, López-Polín A, et al. Safety profile of benznidazole in the treatment of chronic Chagas disease: experience of a referral centre and systematic literature review with meta-analysis. *Drug Saf.* 2018;41:1035–48, <http://dx.doi.org/10.1007/s40264-018-0696-5>.
83. Molina I, Salvador F, Sánchez-Montalvá A, Treviño B, Serre N, Sao Avilés A, et al. Toxic profile of benznidazole in patients with chronic Chagas disease: risk factors and comparison of the product from two different manufacturers. *Antimicrob Agents Chemother.* 2015;59:6125–31, <http://dx.doi.org/10.1128/AAC.04660-14>.
84. Crespillo-Andújar C, Calbacho Robles M, Norman FF, Pérez-Molina JA. Severe immune thrombocytopenia in a patient taking benznidazole for chronic Chagas disease. *BMJ Case Rep.* 2018;24, <http://dx.doi.org/10.1136/bcr-2017-223788>.
85. Da Silva GMS, Mediano MFF, Do Brasil PEAA, Da Costa Chambela M, Silva DJA, De Sousa AS, et al. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole. *Antimicrob Agents Chemother.* 2014;58:6371–7, <http://dx.doi.org/10.1128/AAC.02842-14>.
86. Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. *Antimicrob Agents Chemother.* 2013;57:390–5, <http://dx.doi.org/10.1128/AAC.01401-12>.
87. Crespillo-Andújar C, López-Vélez R, Trigo E, Norman F, Díaz-Menéndez M, Monge-Maillou B, et al. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. *Clin Microbiol Infect.* 2019;26, <http://dx.doi.org/10.1016/j.cmi.2019.03.030>, 384.e11-384.e4.
88. Górgolas M, Robles I, Cabello A, Pérez-Tanoira R, Peremarch CP, Fernández-Roblas R, et al. The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease. *Pathog Glob Health.* 2013;107:157–60, <http://dx.doi.org/10.1179/204773213Y.0000000081>.
89. Docampo R, Mason RP, Mottley C, Muniz RPA. Generation of free radicals induced by nifurtimox in mammalian tissues. *J Biol Chem.* 1981;256:10930–3.
90. Hoffmann K. Toxicological investigations on the tolerability of nifurtimox. *Arzneimittelforschung.* 1972;22:1590–603.
91. Forsyth CJ, Hernandez S, Olmedo W, Abuhamidah A, Traina MI, Sanchez DR, et al. Safety profile of nifurtimox for treatment of Chagas disease in the United States. *Clin Infect Dis.* 2016;63:1056–62, <http://dx.doi.org/10.1093/cid/ciw477>.
92. Olivera MJ, Cucunubá ZM, Álvarez CA, Nicholls RS. Safety profile of nifurtimox and treatment interruption for chronic chagas disease in Colombian adults. *Am J Trop Med Hyg.* 2015;93:1224–30, <http://dx.doi.org/10.4269/ajtmh.15-0256>.
93. Valencia CN, Mancilla M, Ramos D, Zulantay I, Molina M, Torres A. Tratamiento de la enfermedad de Chagas crónica en Chile Efectos adversos de nifurtimox. *Rev Ibero Latinoam Parasitol.* 2012;71:97e108.
94. Jackson Y, Alirol E, Getaz L, Wolff H, Combesure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. *Clin Infect Dis.* 2010;51:e69–75, <http://dx.doi.org/10.1086/656917>.
95. Crespillo-Andújar C, Chamorro-Tojeiro S, Norman F, Monge-Maillou B, López-Vélez R, Pérez-Molina JA. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail. *Clin Microbiol Infect.* 2018;24, <http://dx.doi.org/10.1016/j.cmi.2018.06.006>, 1344.e1–e4.
96. Rassi A, Amato Neto V, Sabbaga Amato V, De Siqueira AF, Ferrioli Filho F, Rassi GG, et al. Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid. *Rev Soc Bras Med Trop.* 2002;35:547–50, <http://dx.doi.org/10.1590/S0037-86822002000600001>.
97. Brener Z, Cançado JR, Galvão LM, da Luz ZM, Filardi LS, Pereira ME, et al. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. *Mem Inst Oswaldo Cruz.* 1993;88:149–53.
98. Venegas J, Zulantay I, Apt W, Solari A, Díaz E, Sánchez G. Effect of itraconazole on lytic antibodies levels in chronic Chagas disease. *Parasite.* 1997;4:259–62.
99. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, Molina J, et al. Antiproliferative effects and mechanism of action of SCH 56592 against *Trypanosoma* (Schizotrypanum) *cruzi*: in vitro and in vivo studies. *Antimicrob Agents Chemother.* 1998;42:1771–7.
100. Molina I, Gomez I, Prat J, Salvador F, Treviño B, Sulleiro E, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. *N Engl J Med.* 2014;370:1899–908, <http://dx.doi.org/10.1056/NEJMoa1313122>.
101. Morillo CA, Waskin H, Sosa-Estani S, del Carmen Bangher M, Cuneo C, Milesi R, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic *T. cruzi* carriers: the STOP-CHAGAS trial. *J Am Coll Cardiol.* 2017;69:939–47, <http://dx.doi.org/10.1016/j.jacc.2016.12.023>.
102. Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo M-J, Schijman A, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. *Lancet Infect Dis.* 2018;18:419–30, [http://dx.doi.org/10.1016/S1473-3099\(17\)30538-8](http://dx.doi.org/10.1016/S1473-3099(17)30538-8).
103. Sánchez-Valdéz FJ, Padilla A, Wang W, Orr D, Tarleton RL. Spontaneous dormancy protects *Trypanosoma cruzi* during extended drug exposure. *Elife.* 2018;7, <http://dx.doi.org/10.7554/eLife.34039>.
104. Mesu VKBK, Kalonji WM, Bardonneau C, Mordt OV, Blesson S, Simon F, et al. Oral fexinidazole for late-stage African *Trypanosoma brucei* gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. *Lancet.* 2018;391:144–54, [http://dx.doi.org/10.1016/S0140-6736\(17\)32758-7](http://dx.doi.org/10.1016/S0140-6736(17)32758-7).
105. Avila JL, Avila AME. Effect of allopurinol on different strains of *Trypanosoma cruzi*. *Am J Trop Med Hyg.* 1981;30:769–74.
106. Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. *Am J Trop Med Hyg.* 1998;59:133–8.
107. Rassi A, Luquetti AO, Rassi A, Rassi GG, Rassi SG, Da Silva JG, et al. Specific treatment for *Trypanosoma cruzi*: lack of efficacy of allopurinol in the human chronic phase of chagas disease. *Am J Trop Med Hyg.* 2007;76:58–61.
108. Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, Petti M, et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of *Trypanosoma cruzi* infection: a pilot study. *J Antimicrob Chemother.* 2013;68:424–37, <http://dx.doi.org/10.1093/jac/dks390>.
109. Benaim G, Paniz Mondolfi AE. The emerging role of amiodarone and dronedarone in Chagas disease. *Nat Rev Cardiol.* 2012;9:605–9, <http://dx.doi.org/10.1038/nrcardio.2012.108>.
110. DNDi. The BENDITA study: a Phase II study to assess safety, tolerability, and efficacy of different benznidazole regimens, alone and in combination with fosravuonazole. 2019:1–2. <https://www.dndi.org/wp-content/uploads/2019/03/2page-BenditastudyOverview>
111. Barreira da Silva Rocha F, Blum B, Sosa Estani S, for the Drugs for Neglected Diseases initiative. Abstract 1853. Evaluating new regimens for the treatment

- of chronic Chagas disease: the BENDITA trial. ASTMH 68th Annual Meeting. Washington November.
112. Álvarez MG, Vigliano C, Lococo B, Petti M, Bertocchi G, Viotti R. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. *Trans R Soc Trop Med Hyg.* 2012;106:636–8, <http://dx.doi.org/10.1016/j.trstmh.2012.07.010>.
  113. Álvarez MG, Hernández Y, Bertocchi G, Fernández M, Lococo B, Ramírez JC, et al. New scheme of intermittent benznidazole administration in patients chronically infected with *Trypanosoma cruzi*: a pilot short-term follow-up study with adult patients. *Antimicrob Agents Chemother.* 2015;60:833–7, <http://dx.doi.org/10.1128/AA.C.00745-15>.
  114. Vallejo A, Monge-Maillo B, Gutiérrez C, Norman FF, López-Vélez R, Pérez-Molina JA. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. *Acta Trop.* 2016;164:117–24, <http://dx.doi.org/10.1016/j.actatropica.2016.09.010>.
  115. Gomes JAS, Bahia-Oliveira LMG, Rocha MOC, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. *Infect Immun.* 2003;71:1185–93, <http://dx.doi.org/10.1128/IAI.71.3.1185-1193.2003>.
  116. Pinazo MJ, Tassies D, Muñoz J, Fisa R, de Jesús E, Monteagudo J, et al. Hypercoagulability biomarkers in *Trypanosoma cruzi*-infected patients. *Thromb Haemost.* 2011;106:617–23, <http://dx.doi.org/10.1160/TH11-04-0251>.
  117. Santamaria C, Chatelain E, Jackson Y, Miao Q, Ward BJ, Chappuis F, et al. Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment. *BMC Infect Dis.* 2014;14, <http://dx.doi.org/10.1186/1471-2334-14-302>.
  118. Zrein M, Granjon E, Gueyffier L, Caillaudeau J, Liehl P, Pottel H, et al. A novel antibody surrogate biomarker to monitor parasite persistence in *Trypanosoma cruzi*-infected patients. *PLoS Negl Trop Dis.* 2018;12:e0006226, <http://dx.doi.org/10.1371/journal.pntd.0006226>.
  119. Ortega-Rodríguez U, Portillo S, Ashmus RA, Duran JA, Schocker NS, Iniguez E, et al. Purification of glycosylphosphatidylinositol-anchored mucins from *trypanosoma cruzi* trypomastigotes and synthesis of  $\alpha$ -Gal-Containing neoglycoproteins: application as biomarkers for reliable diagnosis and early assessment of chemotherapeutic outcomes of Chagas disease. *Methods Mol Biol.* 2019;1955:287–308, [http://dx.doi.org/10.1007/978-1-4939-9148-8\\_22](http://dx.doi.org/10.1007/978-1-4939-9148-8_22).
  120. Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL. New, combined, and reduced dosing treatment protocols cure *Trypanosoma cruzi* infection in mice. *J Infect Dis.* 2014;209:150–62, <http://dx.doi.org/10.1093/infdis/jit420>.
  121. Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. *Br Med Bull.* 2012;104:175–96, <http://dx.doi.org/10.1093/bmb/lds031>.
  122. Manne-Goehler J, Reich MR, Wirtz VJ. Access to care for Chagas disease in the United States: a health systems analysis. *Am J Trop Med Hyg.* 2015;93:108–13, <http://dx.doi.org/10.4269/ajtmh.14-0826>.
  123. Sartor P, Colaiani I, Cardinal MV, Bua J, Freilij H, Gürtler RE. Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation. *PLoS Negl Trop Dis.* 2017;11:e0005336, <http://dx.doi.org/10.1371/journal.pntd.0005336>.
  124. Manne JM, Snively CS, Ramsey JM, Salgado MO, Bärnighausen T, Reich MR. Barriers to treatment access for Chagas disease in Mexico. *PLoS Negl Trop Dis.* 2013;7:e2488, <http://dx.doi.org/10.1371/journal.pntd.0002488>.
  125. Chaves GC, Arrieche MAS, Rode J, Mechali D, Reis PO, Alves RV, et al. Estimación de la demanda de medicamentos antichagásicos: Una contribución para el acceso en América Latina. *Rev Panam Salud Publica/Pan Am J Public Heal.* 2017;41:e45, <http://dx.doi.org/10.26633/RPSP.2017.45>.
  126. Alpern JD, Lopez-Velez R, Stauffer WM. Access to benznidazole for Chagas disease in the United States—cautious optimism? *PLoS Negl Trop Dis.* 2017;11:e0005794, <http://dx.doi.org/10.1371/journal.pntd.0005794>.
  127. Navarro M, de los Santos JJ. Access to Chagas disease treatment in non-endemic countries: the case of Spain. *Lancet Glob Health.* 2017;5:e577, [http://dx.doi.org/10.1016/S2214-109X\(17\)30177-8](http://dx.doi.org/10.1016/S2214-109X(17)30177-8).
  128. Monge-Maillo B, López-Vélez R. Challenges in the management of Chagas disease in Latin-American migrants in Europe. *Clin Microbiol Infect.* 2017;23:290–5, <http://dx.doi.org/10.1016/j.cmi.2017.04.013>.
  129. Prado N. Tratamiento con benznidazol en pacientes adultos con enfermedad de chagas cronica un ensayo clinico aleatorizado (ECA) a doble ciego en fase 3. *Sociedad Argetina de Protozoologia..XXVII Reunion Anual.Libro de Resumenes.* 2015:20.
  130. ClinicalTrials.gov Identifier: NCT02498782. Study to evaluate fexinidazole dosing regimens for the treatment of adult patients with Chagas disease.
  131. ClinicalTrials.gov Identifier: NCT02369978. CHICAMOCHA 3 – equivalence of usual interventions for Trypanosomiasis (EQUITY) (CHICAMOCHA-3).
  132. ClinicalTrials.gov Identifier: NCT03191162. Evaluation of different benznidazole regimens for the treatment of chronic Chagas disease (MULTIBENZ).
  133. ClinicalTrials.gov Identifier: NCT03193749. A trial testing amiodarone in Chagas cardiomyopathy (ATTACH).
  134. ClinicalTrials.gov Identifier: NCT03672487. Short-course benznidazole treatment to reduce *Trypanosoma cruzi* parasitic load in women of reproductive age (BETTY).